{
    "clinical_study": {
        "@rank": "67209", 
        "acronym": "TREAT-ME 1", 
        "arm_group": {
            "arm_group_label": "treatment arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerability of MSC_apceth_101."
        }, 
        "brief_title": "Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101", 
        "condition": "Advanced Gastrointestinal Cancer", 
        "condition_browse": {
            "mesh_term": "Gastrointestinal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma.\n\n          -  Premature or scheduled termination of standard therapy\n\n          -  Progressive disease as clinically assessed by the investigator\n\n          -  Max. tumour lesion \u2264 5 cm\n\n          -  Adequate organ function\n\n          -  Ability of patient to understand character and individual consequences of clinical\n             trial\n\n          -  Age \u2265 18 years\n\n          -  Written informed consent must be available before any study specific procedure is\n             performed\n\n        Exclusion Criteria:\n\n          -  Patients with severe heart diseases\n\n          -  Clinical significant ischemic disease during the last 4 weeks before Visit 1\n\n          -  Severe lung disease\n\n          -  Symptomatic peritoneal carcinomatosis\n\n          -  Symptomatic pleural or pericardial effusion\n\n          -  Serious uncontrolled acute infections less than 3 weeks before Visit 1\n\n          -  Known dependency on alcohol or other drugs\n\n          -  Patients requiring corticoids in doses above the Cushing threshold\n\n          -  Known liver fibrosis or liver cirrhosis\n\n          -  Any concomitant severe disease which could compromise the objectives of this study in\n             the judgment of the investigator\n\n          -  Female patient who is pregnant or breast feeding\n\n          -  Participation in another clinical trial or observation period, respectively, during\n             the last 4 weeks prior to the first IMP dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008539", 
            "org_study_id": "MSC_apceth_101/1"
        }, 
        "intervention": {
            "arm_group_label": "treatment arm", 
            "intervention_name": "MSC_apceth_101", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Munich", 
                    "country": "Germany", 
                    "zip": "81377"
                }, 
                "name": "University Hospital Munich"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101", 
        "overall_contact": {
            "email": "info@apceth.com", 
            "last_name": "apceth GmbH & Co.KG", 
            "phone": "+49 89 7009608", 
            "phone_ext": "0"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute", 
            "safety_issue": "Yes", 
            "time_frame": "day 56 (+/- 7) in patient group 1 and day 29 (+/-3) in patient group 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008539"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Apceth GmbH & Co. KG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Apceth GmbH & Co. KG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}